NEW YORK – DNAnexus and Galatea Bio have entered into a strategic collaboration to accelerate the analysis of genomic datasets of non-European origin.
Under the agreement, the financial details of which were not disclosed, Galatea Bio will use DNAnexus' Precision Health Data Cloud to manage, analyze, and broaden the accessibility of genomic datasets of non-European origin. DNAnexus has the opportunity to leverage Galatea's local ancestry and ancestry-adjusted polygenic risk score algorithms for its own network of over 48,000 users across 48 countries.
"DNAnexus is committed to advancing health equity for all individuals around the world," DNAnexus CEO Thomas Laur said in a statement. "Galatea Bio is filling an enormous unmet need in precision health with these larger, non-European cohort studies."
DNAnexus recently initiated a broad restructuring program and inked several agreements aimed at improving genomic analyses through better artificial intelligence models.
Earlier this year, the Mountain View, California-based company signed separate agreements with Oracle and with Nvidia Microservices to integrate the companies' various precision health data analysis products.